A baseline process for the production, recovery, and purification of bacterial influenza vaccine candidates. - sprookjes - yvandenbroek - TriplyDB

A baseline process for the production, recovery, and purification of bacterial influenza vaccine candidates.

A baseline process for the production, recovery, and purification of bacterial influenza vaccine candidates.

http://www.wikidata.org/entity/Q30431659

about

The E. coli pET expression system revisited-mechanistic correlation between glucose and lactose uptake.Refolding and purification of recombinant human (Pro)renin receptor from Escherichia coli by ion exchange chromatography.

P2860

Q41175222-7DD2D670-597F-4560-901A-9B6DB2F9B74B Q54291321-130C5E0E-4D40-4873-A5CB-79715BE1F03E

P2860

A baseline process for the production, recovery, and purification of bacterial influenza vaccine candidates.

http://www.wikidata.org/entity/Q30431659

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A baseline process for the pro ...... influenza vaccine candidates.

@ast

A baseline process for the pro ...... influenza vaccine candidates.

@en

type

label

A baseline process for the pro ...... influenza vaccine candidates.

@ast

A baseline process for the pro ...... influenza vaccine candidates.

@en

prefLabel

A baseline process for the pro ...... influenza vaccine candidates.

@ast

A baseline process for the pro ...... influenza vaccine candidates.

@en

P1433

Q30431659-CA96D4D7-69A6-4060-9F06-16B450C7B72B

P1476

Q30431659-A591AD3C-6DB1-4F15-8DED-130C11C9E1A5

P2093

Q30431659-00FF5231-AA17-45A7-8EDB-DC6C922D157A

Q30431659-452589B7-FA69-452A-8A79-A874E17AD894

Q30431659-53AEB2FD-9459-4DD0-B976-CDDF811C60F3

Q30431659-B3F5E12F-211E-403F-9D0E-22B6DE75E928

Q30431659-E2BD2B9E-1AF0-4C40-9934-01BB90DB7323

Q30431659-E8FAEF4A-3876-4481-B2B6-01358A9D27B8

Q30431659-F038F85A-1D81-4FF1-8429-D9D306A42B01

P2860

Q30431659-0485801A-659B-4CA4-824D-7A63C1AF7869

Q30431659-16821680-8B17-45DB-B18B-6BB6D865EDC8

Q30431659-1A3BE566-7F87-45FC-BA42-D54BBD0E50AA

Q30431659-226FF0B4-A16A-43A8-A0DC-166741FBC2C9

Q30431659-299C1E09-7362-4BD8-B8AC-B048954D9B12

Q30431659-3A4F00F2-B9DF-47C6-89B7-7A3AEBDFC7E2

Q30431659-3BEC4859-4C03-4F7B-9663-FCAE9BD98AB3

Q30431659-5D6C451A-F4B7-4472-BBAF-69CCB9E6B045

Q30431659-5F11BB54-BF58-4F2E-813C-D68179856F12

Q30431659-6ACF038C-AD30-4211-90CE-44AF8D4331CB

P304

Q30431659-A5875486-EB97-4F33-A2F3-9C92E5E7FD38

P31

Q30431659-887C38EF-B77D-42FC-BFF9-4EE9E1A2CB10

P356

Q30431659-CB441924-90EF-4791-ABC8-2B20C9BBCEE4

P433

Q30431659-B8152FB8-03C0-4E99-BCF1-5245926A0164

P478

Q30431659-884F5016-8F9B-46FC-BDEA-7246081F2BBC

P50

Q30431659-0EFB3583-B7D4-413F-AD61-8DD11BCC7374

Q30431659-243C1CBE-117F-480A-85D9-A3871BF50BD9

Q30431659-5FBA5983-B56F-42F0-8EB4-6251CD30B0A0

Q30431659-C86D9737-DFA3-46B7-9462-8EAD51430535

P577

Q30431659-884EB1A3-50BF-4713-9972-40D13A926C28

P698

Q30431659-1396D451-2D98-4F1F-85D3-78013935DE5A

P356

P1433

Biotechnology Progress

P1476

A baseline process for the pro ...... l influenza vaccine candidates

@en

P2093

Alicia Ramírez-Medrano

http://www.w3.org/2001/XMLSchema#string

Felipe López-Pacheco

http://www.w3.org/2001/XMLSchema#string

Juan C González-Vázquez

http://www.w3.org/2001/XMLSchema#string

Pamela B Sánchez-Arreola

http://www.w3.org/2001/XMLSchema#string

Pedro Soto-Vázquez

http://www.w3.org/2001/XMLSchema#string

Roberto Pérez-Chavarría

http://www.w3.org/2001/XMLSchema#string

Salvador López-Uriarte

http://www.w3.org/2001/XMLSchema#string

P2860

Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin

The Receptor-Binding Domain of Influenza Virus Hemagglutinin Produced in Escherichia coli Folds into Its Native, Immunogenic Structure

Solubilization and refolding of bacterial inclusion body proteins

An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli

The annual impact of seasonal influenza in the US: Measuring disease burden and costs

Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels

Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium.

Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge.

Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

P304

896-908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BTPR.1749

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Mario Moisés Alvarez

Maria Del Refugio Rocha-Pizaña

María R Rocha-Pizaña

Pável A Marichal-Gallardo

P577

2013-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23749362

http://www.w3.org/2001/XMLSchema#string